argenx SE (1AE.F)
| Previous close | 355.00 |
| Open | 350.60 |
| Bid | 344.60 x 0 |
| Ask | 355.00 x 0 |
| Day's range | 350.60 - 350.60 |
| 52-week range | 278.90 - 490.50 |
| Volume | |
| Avg. volume | 4 |
| Market cap | 20.837B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.80 |
| Earnings date | 25 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider Monkeyargenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript May 9, 2024 argenx SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Rob and I will be your conference operator today. I would like to welcome […]
GlobeNewswireargenx Reports First Quarter 2024 Financial Results and Provides Business Update
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announc
ZacksIs a Surprise Coming for argenx (ARGX) This Earnings Season?
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
